

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 424 095 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
02.06.2004 Bulletin 2004/23

(51) Int Cl.7: **A61N 1/05**, B21C 37/00,
C23C 16/00

(21) Application number: 03257446.9

(22) Date of filing: 26.11.2003

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**
Designated Extension States:
AL LT LV MK

(72) Inventors:
• **O'Brien, Robert C.**
Sykesville Maryland 21784 (US)
• **Frysz, Christine**
Columbia Maryland 21045 (US)

(30) Priority: 26.11.2002 US 429471 P

(74) Representative: **Colmer, Stephen Gary et al**
Mathys & Squire
100 Gray's Inn Road
London WC1X 8AL (GB)

(71) Applicant: **Wilson Greatbatch Technologies, Inc.**
Clarence, New York 14031 (US)

(54) **Nanotube coatings for implantable electrodes**

(57) Coatings for implantable electrodes consisting of single- or multi-walled nanotubes, nanotube ropes, carbon whiskers, and a combination of these are described. The nanotubes can be carbon or other conductive nanotube-forming materials such as a carbon-doped boron nitride.
The nanotube coatings are grown "*in situ*" on a catalytic

substrate surface from thermal decomposition, or they are bonded to the substrate using a metal or conductive metal oxide thin film binder deposited by means of a metal compound precursor in liquid form. In the latter case, the precursor/nanotube coating is then converted to a pure metal or conductive metal oxide, resulting in the desired surface coating with imbedded nanotubes.




FIG. 1

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

[0001] This invention generally relates to coatings for implantable electrodes such as pacing electrodes, neurostimulator electrodes, and electroporating electrodes and sensing electrodes. The three overriding requirements for these types of electrodes are biocompatibility, biostability, and low energy loss. Broadly, the biocompatibility requirement is met if contact of the electrode with body tissue and blood results in little or no immune response from the body, especially thrombogenicity (clotting) and encapsulation of the electrode with fibrotic tissue. The biostability requirement means that all physical, electrical, and chemical properties of the electrode/coating system remain constant and unchanged over the life of the patient. The low energy loss requirement is met if electrode polarization is a minimum.

2. Prior Art

[0002] U.S. Patent No. 4,602,637 to Elmqvist describes a commonly used pacing electrode having sputtered columnar titanium nitride as a coating material. This form of titanium nitride has good conductivity combined with a high specific surface area, resulting in favorable polarization and sensing properties. The disadvantage of titanium nitride, however, is that it degrades the electrical properties of surrounding tissue after implantation. This occurs as the body tissue encapsulates the columnar titanium nitride in fibrotic tissue, which has a lower conductivity than normal tissue.

[0003] In the case of a pacing electrode, fibrotic tissue raises the stimulation threshold. The stimulation threshold is the minimum energy required to produce a cardiac contraction. This, in turn, impacts the battery life of the system so that the medical device must be explanted sooner than desired. The encapsulation process also interferes with sensing of intrinsic millivolt signals required by pacemakers. In prior electrode designs, the fibrotic encapsulation problem has been addressed by incorporating a means of metering or eluting steroidal medication to the site of tissue contact over time. However, eluting a steroidal medication to the implant site is not completely effective in eliminating the stimulation threshold rise due to encapsulation. Steroidal medication eluting arrangements have a short duration of effectiveness, and also add cost and complexity to the system, add the risk of infection, and, in many cases, a portion of the electrode working surface must be dedicated to the medication administering function.

[0004] Other efforts to overcome the problem of fibrotic encapsulation are described in U.S. Patent Nos. 4,495,039 to Cerise et al. and 4,612,100 to Edeling et al. The former patent relates to electrodes made of py-

rolytic carbon while the latter is directed to electrodes coated with amorphous sputtered carbon. These designs meet the requirement of improved biocompatibility, but they do not have the high specific surface characteristics of columnar titanium nitride, and so fall short in polarization and sensing properties.

SUMMARY OF THE INVENTION

[0005] The present coating consists of a substrate surface layer comprised of conductive carbonaceous nanotubes or nanotubes of other biocompatible, conductive material. The nanotubes are in the form of single-wall nanotubes (below about 2 nanometers in diameter), multiwall nanotubes (structure of concentric tubes), nanotube ropes, carbon whiskers, and a combination thereof. Multiwall nanotubes are nanotubes grown concentrically. Nanotube ropes consist of a multitude of single- or multi-walled nanotubes bundled in parallel until the diameter increases, typically to about 10 nm to about 100 nm. Nanotube ropes originate at the substrate and grow outward. They can grow into a parallel, close-packed morphology, or into a tangled "hairy" morphology. In either case, the result is a layer consisting of a multitude of nanotubes, each attached at one or both ends to the substrate. The nanotubes can be carbonaceous, or of other conductive and biocompatible nanotube-forming materials, such as carbon-doped boron nitride.

[0006] The resulting electrode is both biocompatible and biostable because the nanotube coating is covalently bonded to the electrode surface. Advantageously, the electrode exhibits relatively low polarization because of the greatly increased surface area imparted by the nanotubes. In that respect, the nanotube coating mimics the physical structure of the conventional sputter coated columnar titanium nitride. However, the excellent biocompatibility of nanotube coatings advantageously lessens or eliminates the requirement for a means of providing steroidal medication to the tissue surrounding the electrode.

[0007] These and other aspects of the present invention will become increasingly apparent to those skilled in the art by reference to the following description and to the appended drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0008]

Fig. 1 is a photograph of nanotube ropes grown on a titanium substrate from acetylene at 650°C at 100,000x magnification.

Figs. 2A and 2B are photographs at 50,000 magnification of nanotube whiskers grown on a titanium substrate from methyl acetylene-propadiene gas bubbled through ammonium hydroxide at 550°C and 650°C, respectively.

Figs. 3A and 3B are photographs showing a nanotube coating grown *in-situ* on a tantalum substrate according to one embodiment of the present invention at magnifications of 20,000x and 50,000x, respectively.

Fig. 4 is a photograph at 20,000x magnification showing a layer of nanotubes bonded to a glass surface using an iridium oxide binder according to another embodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] One preferred embodiment for making a nanotube-coated electrode is by high temperature hydrocarbon decomposition on a substrate. The substrate material must be biocompatible, electrically conductive, and capable of nucleating or catalyzing the desired nanotube structures. Preferred substrate materials include tantalum, titanium, zirconium, platinum, iridium, and niobium. A different base material can be used if the substrate is provided with a coating of these metals or with a coating of a nitride, carbide, carbonitride, or oxide of these metals. An example of this is a tantalum coating on a titanium substrate. Both materials are biocompatible, however, titanium is less expensive than tantalum.

[0010] Carbon is another preferred catalyst material for growing nanotubes. Preferably, the carbon is in the form of a machined vitreous carbon electrode or as a thin film carbonaceous coating over a machined metal electrode. Sputtering is one preferred method for applying a relatively thin film carbon coating, in which case the coating consists of amorphous carbon. In particular, if the sputtered amorphous carbon is doped with nitrogen, such as by the presence of nitrogen in the sputter process gas, then the resulting film is an effective catalyst for subsequent growth of nanotubes. If nitrogen is provided, it is preferably at a concentration of about 1 to about 57 atomic percent. The advantage of this carbon nanotube/carbon catalyst system is that the electrode-tissue interface is limited to various allotropes of carbon, which are highly biocompatible materials. That is, when the metal substrate is first provided with sputtered amorphous carbon, it is prevented from being exposed to body fluids and body tissue. If the catalyst layer were a biocompatible metal rather than carbon, the porous nanotube layer would allow the metal to be exposed to body fluids and tissue.

[0011] U.S. Patent Nos. 5,872,422 and 5,973,444, both to Xu et al., describe a conventional process for growing a carbon fiber on a metallic substrate, such as for use in a picture tube. However, the present invention has adapted this process for the production of a nanotube-coated electrode. The process begins with a shaped electrode substrate made of or coated with the appropriate catalyst material first being placed in a closed chamber with a flowing hydrogen atmosphere. The chamber is heated to a temperature from about

350°C to about 1150°C, more preferably from about 550°C to about 850°C. When the desired temperature is reached, the hydrocarbon flow is started. Hydrocarbons useful for growing nanotubes are gaseous and include acetylene, methyl acetylene-propadiene (MAPP) gas, and a gas from the paraffin series, i.e., methane, ethane, propane, butane, pentane, etc. and mixtures thereof. Additionally, having been bubbled through an ammonium hydroxide solution can provide the hydrocarbon with an ammonia addition. A typical coating formation time is about 5 minutes to about 1 hour, preferably about 15 minutes. Cooling is done in hydrogen. The resulting nanotubes are generally classified as being nanotube ropes.

[0012] Plasma assisted chemical vapor deposition is another preferred method for making a nanotube-coated electrode substrate. The plasma assisted CVD process can be performed by microwave excitation, or by other means. This process is preferred because the resulting nanotube arrays are more highly aligned, which is an objective in attempting to mimic a conventional columnar titanium nitride coating.

[0013] The morphology of the nanotubes is partially impacted by the hydrogen source gas. For example, acetylene at about 650°C gives nanotube ropes about 20 to 50 nm in diameter (Fig. 1). Changing to MAPP gas bubbled through NH_3OH with a heating temperature of about 550°C results in coarse, more tightly adhering, oriented spiky carbon whiskers (Figs. 2A and 2B).

[0014] Alternatively, bulk loose nanotubes are attached to the electrode surface by means of a thin film binder coating consisting of a biocompatible metal or conductive metal oxide deposited by means of a metal compound precursor in liquid form. The basic method of thin film deposition is described in greater detail in U. S. Patent No. 4,919,135 to Phillips, which is incorporated herein by reference. Bulk nanotubes are commercially available from numerous sources; for example: Nanostructured and Amorphous Materials, Inc (Los Alamos, NM). Suitable binder precursors include chloroiridic acid (hydrogen hexachloroiridate IV hydrate), chloroplatinic acid, titanium (IV) chloride, zirconium (IV) chloride, niobium (V) chloride, tantalum (V) chloride, and mixtures thereof. The binder is prepared at room temperature by first dissolving the precursor compound of the biocompatible metal in a solvent. Preferred solvents are alcohols such as *tert*-butanol, isopropanol, and ethanol.

[0015] Loose nanotubes are then mixed into the precursor solution at a high shear rate. The resulting homogeneous mixture is applied to the electrode surface as a thin film by dipping, spraying, doctor blading, by dropper application, or otherwise contacting the metal compound/solvent/nanotube mixture thereto. Solvent removal is by drying the substrate in a warmed atmosphere. This produces a thin metal compound/nanotube layer on the electrode surface. A low temperature heat treatment converts the metal compound layer to a metal/nanotube or metal oxide/nanotube composite thin film.

This heating step is carried out at a temperature of about 300°C to about 500°C for a time ranging from about 30 minutes to about 3 hours. The resulting thin film has a thickness of about 100 to 500 nanometers, and resembles a porous metal matrix composite with the biocompatible conductive metal oxide or metal as the matrix and the nanotubes being the second phase.

[0016] In the case of an iridium oxide binder formed from chloroiridic acid, iridium metal is easily oxidized, and a metal oxide binder results. The preferred converting atmosphere is air. In the case of a binder of platinum, titanium, zirconium, niobium, and tantalum, the respective platinum, titanium, zirconium, niobium, and tantalum metals do not oxidize at the temperatures used. Instead, heating the precursors of these metals in an inert atmosphere, such as of argon, nitrogen, helium, and a vacuum, is expected to result in a metal binder.

[0017] The following examples describe the manner and process of a nanotube-coated substrate according to the present invention, and set forth the best mode contemplated by the inventors of carrying out the invention.

EXAMPLE I

[0018] A tantalum substrate was placed in a closed chamber. The chamber was heated to about 650°C with hydrogen gas flowing through the chamber at a rate of about 1 liter/min. for about every 20 cc of reactive volume. When the reaction chamber reached the desired temperature, 0.5 liter/min of acetylene was added to the reaction gas stream. After about 15 minutes, it was observed that a useable nanotube coating had grown *in-situ* on the tantalum substrate. The photographs in Figs. 3A and 3B show the resulting *in-situ* grown nanotube coating on the tantalum substrate at magnifications of 20,000x and 50,000x, respectively.

[0019] A useable nanotube coating can be grown in a similar manner on a substrate of titanium, zirconium, iridium, platinum, niobium, and nitrogen-doped amorphous carbon, or virtually any substrate provided with a thin film coating of these materials. These catalytic or nucleating materials have biocompatible properties similar to those of tantalum.

EXAMPLE II

[0020] Etching in aqueous oxalic acid solution at 80°C for 1 hour cleaned a titanium electrode tip.

[0021] A chloroiridic acid solution was prepared by dissolving 1 gram of chloroiridic acid in 35 ml of isopropyl alcohol at room temperature with stirring. Loose nanotube powder was then added while stirring at a high shear rate until a thick, viscous mixture was obtained. The iridium oxide coated substrate was then dipped into the mixture to provide a viscous coating of nanotubes thereon. Heating the coated substrate to about 340°C in air for about 1 hour converted the metal chloride to

iridium metal, which was then subsequently oxidized by further heating. The iridium oxide coated substrate had embedded nanotubes.

[0022] The photograph in Fig. 4 shows a similarly generated nanotube coating bonded to a PYREX® glass substrate with iridium oxide binder at a magnification of 20,000x. While the experiment was done with a titanium electrode tip, the reason for the glass substrate was because glass is easily fractured and then viewed edge-on in the SEM in order to image a cross section of the thin film coating. With submicron coatings it is very difficult to get a cross section from the titanium part itself. PYREX® glass was used because it withstands the 340°C heat treatment without softening or shattering.

Claims

1. An implantable electrode, which comprises:

- a) a substrate;
- b) a biocompatible and electrically conductive catalysing coating supported on the substrate; and
- c) a multiplicity of carbon-containing nanotubes adhering to the coating.

2. An implantable electrode which includes a multiplicity of carbon-containing nanotubes adhering to the outermost of a substrate or, optionally, a coating thereon, at least the outermost of the substrate and coating (where present) being:

- biocompatible;
- electrically conductive; and
- capable of nucleating or catalysing the formation of the nanotubes.

3. The electrode of Claim 1 or Claim 2 wherein the substrate is selected from the group consisting of tantalum, titanium, zirconium, iridium, platinum and niobium.

4. The electrode of any one of the preceding claims wherein the coating is selected from the group consisting of tantalum, titanium, zirconium, iridium, platinum, niobium and nitrogen-doped carbon.

5. The electrode of Claim 4 wherein the nitrogen in the nitrogen-doped carbon is provided at a concentration of 1 to 57 atomic percent.


6. The electrode of any one of Claims 1 to 3 wherein the coating is selected from the group consisting of a nitride, a carbide, a carbonitride and an oxide of the group of tantalum, titanium, zirconium, iridium, platinum and niobium.

7. The electrode of any one of the preceding claims wherein the nanotubes are in a form selected from the group consisting of single-wall nanotubes, multi-wall nanotubes, nanotube ropes, carbon whiskers, and combinations thereof.
8. The electrode of any one of the preceding claims wherein the nanotubes are preparable from a reaction gas selected from the group consisting of acetylene, methyl acetylene-propadiene and a gas of the paraffin series.
9. The electrode of Claim 8 wherein the reaction gas includes ammonia.
10. The electrode of Claim 1 or Claim 2 comprising the nanotubes adhering to tantalum coated on the titanium substrate.
11. A method for providing an implantable electrode, comprising the steps of:
 - a) providing a substrate;
 - b) if desired, coating a catalytic material selected from the group consisting of nitrogen-doped carbon, tantalum, titanium, zirconium, iridium, platinum and niobium or a nitride, a carbide, a carbonitride and an oxide of tantalum, titanium, zirconium, iridium, platinum or niobium on the substrate;
 - c) heating the coated substrate;
 - d) contacting the heated substrate with a flowing hydrocarbon-containing gas stream to thereby provide carbon-containing nanotubes on the coated substrate; and
 - e) utilizing the nanotube coated substrate as an implantable electrode.
12. The method of Claim 11 including heating the coated substrate to a temperature of 350°C to 1,150°C.
13. The method of Claim 11 or Claim 12 including cooling the nanotube coated substrate in hydrogen prior to use.
14. A method of providing an implantable electrode, comprising the steps of:
 - a) providing a substrate;
 - b) providing nanotubes mixed with a binder precursor selected from chloroiridic acid, chloroplatinic acid, titanium (IV) chloride, zirconium (IV) chloride, niobium (V) chloride, and tantalum (V) chloride in a solvent;
 - c) contacting the binder precursor to the substrate;
 - c) converting the binder precursor to coating on the substrate having the nanotubes embedded
- therein.
15. The method of Claim 14 including heating the binder precursor coated substrate in either an oxidizing or an inert atmosphere.
16. The method of Claim 14 or Claim 15 including heating the binder precursor coated substrate at a temperature of 300°C to 500°C.
17. The method of any one of Claims 14 to 16 including heating the binder precursor coated substrate for a time from 30 minutes to 3 hours.
18. The method of any one of Claims 14 to 17 including heating the chloroiridic acid binder precursor in an oxidizing atmosphere to provide the nanotubes embedded in an iridium oxide binder coated on the substrate.
19. The method of any one of Claims 14 to 18 including heating the chloroplatinic acid, titanium (IV) chloride, zirconium (IV) chloride, niobium (V) chloride, and tantalum (V) chloride binder precursors in an inert atmosphere to provide the nanotubes embedded in a binder of platinum, titanium, zirconium, niobium, and tantalum, respectively, coated on the substrate.
20. A method for providing an implantable electrode, comprising the steps of:
 - a) providing a substrate;
 - b) coating a carbonaceous catalytic material on the substrate;
 - c) heating the carbonaceous coated substrate;
 - d) contacting the heated substrate with a flowing hydrocarbon-containing gas stream to thereby provide carbon-containing nanotubes on the carbonaceous coated substrate; and
 - e) utilizing the nanotube coated substrate as an implantable electrode.
21. The method of Claim 20 including heating the carbonaceous coated substrate to a temperature of 350°C to 1,150°C.
22. The method of Claim 20 or Claim 21 including sputtering the carbonaceous catalytic material on the substrate.
23. The method of any one of Claims 20 to 22 including providing the sputtered carbonaceous catalytic material as nitrogen-doped carbon.
24. The method of any one of Claims 20 to 23 including providing the nitrogen in the nitrogen-doped carbon at a concentration of 1 to 57 atomic percent.


25. A method for providing an implantable electrode comprising the steps of:

- a) providing a substrate;
- b) if desired, coating a catalytic material selected from the group consisting of nitrogen-doped carbon, tantalum, titanium, zirconium, iridium, platinum, and niobium or a nitride, a carbide, a carbonitride, and an oxide thereof on the substrate;
- c) subjecting the coated substrate to a plasma assisted chemical vapor deposition process containing a flowing hydrocarbon-containing gas stream to thereby provide carbon-containing nanotubes on the coated substrate; and
- d) utilizing the nanotube coated substrate as an implantable electrode.

26. The method of Claim 25 including utilizing microwave excitation in the plasma assisted chemical vapor deposition process.



—FIG. 1




—FIG. 4

BEST AVAILABLE COPY




—FIG. 2A



—FIG. 2B



—FIG. 3A



—FIG. 3B



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 03 25 7446

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	EP 0 453 117 A (CARDIAC PACEMAKERS) 23 October 1991 (1991-10-23) * abstract; claim 1; figure 1 *	1-26	A61N1/05 B21C37/00 C23C16/00
Y	WO 02 068323 A (CROCI MIRKO ;BONARD JEAN-MARC (CH); NANOLIGHT INTERNAT LTD (CH)) 6 September 2002 (2002-09-06) * claim 1; figure 1 *	1-13	
Y	US 2002/055010 A1 (GAO YUFEI ET AL) 9 May 2002 (2002-05-09) * paragraphs [0019]-[0022]; claim 1 *	14-24	
Y	US 2002/150684 A1 (JAYATISSA AHALAPITIYA H) 17 October 2002 (2002-10-17) * abstract; claim 1 *	25,26	
A,P	US 2003/091825 A1 (HAWORTH MICHAEL D ET AL) 15 May 2003 (2003-05-15) * the whole document *	1-26	
A	US 5 964 794 A (WAGNER ROLAND ET AL) 12 October 1999 (1999-10-12) * abstract; claim 1 *	1-26	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search MUNICH		Date of completion of the search 5 February 2004	Examiner Chopinaud, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 25 7446

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-02-2004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0453117 A	23-10-1991	US 5074313 A	24-12-1991
		AT 130773 T	15-12-1995
		CA 2039125 A1	21-10-1991
		DE 69114895 D1	11-01-1996
		DE 69114895 T2	23-05-1996
		EP 0453117 A1	23-10-1991
		JP 2574075 B2	22-01-1997
		JP 4227276 A	17-08-1992
-----	-----	-----	-----
WO 02068323 A	06-09-2002	WO 02068323 A1	06-09-2002
-----	-----	-----	-----
US 2002055010 A1	09-05-2002	US 2002004136 A1	10-01-2002
		AU 7824400 A	02-01-2001
		WO 0076912 A2	21-12-2000
-----	-----	-----	-----
US 2002150684 A1	17-10-2002	NONE	
-----	-----	-----	-----
US 2003091825 A1	15-05-2003	WO 03043046 A1	22-05-2003
-----	-----	-----	-----
US 5964794 A	12-10-1999	DE 19630563 A1	25-09-1997
		EP 0796634 A2	24-09-1997
-----	-----	-----	-----

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)